ClinicalTrials.gg
TerminatedNCT02149277Updated Apr 27, 2022

Gcsf Injection in Women With Repeated Implantaiton Failure

A Phase 3 interventional study of Filgrastim in Repeated Embryo Implantation Failure, sponsored by Clinique Ovo. Terminated at 1 site in Canada. Open to female participants aged 18 Years to 37 Years. Per ClinicalTrials.gov, last updated 2022-04-27.

Sponsored by Clinique Ovo · Phase 3, Interventional, and Treatment

Why this study was terminated
Recruitment difficulty

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Mar 2013, registered Mar 2014).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 37 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies in Infertility by Clinique Ovo — none open to participants now, none under way, none of them phase 3. Infertility · Clinique Ovo.

Started
2013
with 1 other
Phase 3
2 of 20
none open now
Registered
10th of 20
by date

Among the 20 studies in Infertility by Clinique Ovo, this one is one of 2 that started in 2013, is one of 2 in phase 3, and was the 10th registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 356 are open to participants now.

Browse Infertility studies →

Open to participants now

None of the 20 studies in Infertility by Clinique Ovo is open now. The open studies under Infertility, anywhere →

Where they have run

Who these studies take

Of the 234 Infertility studies recruiting now, 43 (18%) set no upper age limit and 185 (79%) stop at 75 or younger; 27 take children under 18; 76 take healthy volunteers.

This study: 18 Years to 37 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Infertility by Clinique Ovo as a file.
02

Study summary

The purpose of the study is to see the impact of intrauterine injection of recombinant GCSF on pregnancy and implantation rate during IVF-ICSI (intracytoplasmic sperm injection) protocols as well as in frozen embryo transfer. In addition, following the injection, the level of G-CSF in the bloodstream will be verified.

Read the detailed description

Recently, scientists have been interested in G-CSF (Granulocyte - Colony Stimulating Factor) and the latter has seen its use grow in reproductive pathology.

G -CSF, a true center pivot, would act concurrently on oocyte quality and endometrial receptivity, improving:

  • Immune tolerance
  • The self-healing of oocyte chromosome abnormalities
  • The adherence of the embryo

The injection of G-CSF molecule has been used in different circumstances. One of its uses, among others, is to help rebuild the immune system in patients undergoing chemotherapy. Some studies have been conducted in patients having embryo implantation problems; they have demonstrated improved rates of pregnancy and childbirth after treatment.

03

Conditions studied

  • Repeated Embryo Implantation Failure

Browse trials for

Keywords

  • Infertility
  • IVF
  • Embryo transfer
04

Who can participate

Ages eligible
18 Years to 37 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women between the ages of 18 and 37
  • Indication of the Antagonist IVF protocol or indication of a substituted frozen embryo transfer
  • Subjects with repetitive embryo implantation failure meaning: a history of 3 embryos transferred including frozen embryo without a positive pregnancy test for women 35 years and younger
  • Subjects with repetitive embryo implantation failure meaning: a history of 4 embryos transferred including frozen embryo without a positive pregnancy test for women between the ages of 35 and 37.
  • Negative repetitive implantation failure work up

Exclusion criteria

Exclusion Criteria:

  • Renal failure or cardiac failure
  • Chronic neutropenia
  • Past or present cancer history
  • Sickle cell anemia
  • Lithium treatment
  • Voluntary withdrawal from the study
  • Use of concomitant medication: DHEA (dehydroepiandrosterone ), CoQ10 (coenzyme Q10), Growth Hormone and Viagra
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
15 participants (actual)

Study arms

  • Active comparator
    Filgrastim

    Injection Filgrastim 300 ug intravaginally during an IVF cycle or during an embryo transfer

    Drug: Filgrastim

  • Placebo comparator
    Sodium Chloride

    Injection of 1 ml of Sodium Chloride intravaginally during an IVF cycle or during an embryo transfer cycle.

    Drug: Filgrastim

Interventions

  • The fertility specialist will inject the study medication or its placebo on the 6th day of gonadotrophin stimulation for IVF subjects. For the subjects undergoing embryo transfer, the injection will be done once the endometrial lining measure more than 8mm.

    Also known as: Neupogen

06

What researchers measure

Primary outcomes

  1. Dosage of G-CSF

    Measure dosage of G-CSF in the bloodstream on the day of oocyte retrieval and measure the implantation rate as well as pregnancy rate following the G-CSF injection

    Time frame: up to 3 years

  2. Pregnancy and Implantation

    Measure the pregnancy and embryo implantation rate post G-CSF injection

    Time frame: up to 3 years

07

Study locations

1 site
  • Clinique Ovo
    Montreal, Quebec H4P 2S4, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2013 to primary completion in Dec 2017, 57 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2014
First posted
May 29, 2014
StartActual
Mar 2013
Primary completionActual
Dec 2017
CompletionActual
Dec 2017
Last update
Apr 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02149277
Lead sponsor
Clinique Ovo
Responsible party
Sponsor
First posted
May 29, 2014
Start date
Mar 2013
Primary completion
Dec 2017
Completion
Dec 2017
Last update
Apr 27, 2022

Study contacts

Jacques Kadoch, Md
principal investigator · Clinique Ovo

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Filgrastim

Start the discussion